865466-24-6
Chemical Structure
Narlaprevir
Synonym(s): SCH 900518
- CAS No.: 865466-24-6
- Formula:C36H61N5O7S
- Molecular Weight:707.96
IUPAC Name: (1R,2S,5S)-3-((S)-2-(3-(1-((tert-butylsulfonyl)methyl)cyclohexyl)ureido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
InChIKey: RICZEKWVNZFTNZ-LFGITCQGSA-N
SMILES: O=S(CC1(NC(N[C@H](C(N2[C@@H]([C@@]3([H])C(C)([C@]3(C2)[H])C)C(N[C@H](C(C(NC4CC4)=O)=O)CCCC)=O)=O)C(C)(C)C)=O)CCCCC1)(C(C)(C)C)=O
Biological Activity: Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM[1]. Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease[2]. Narlaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.3 μM[3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Narlaprevir | 95.88% | Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM. Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease. Narlaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.3 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Narlaprevir (Standard) | ≥98% | Narlaprevir (Standard) is the analytical standard of Narlaprevir. This product is intended for research and analytical applications. Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM. Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease. Narlaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.3 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ashok Arasappan, et al. Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor. ACS Med Chem Lett. 2010 Feb 15;1(2):64-9. [Content Brief]
- [2]. X Tong, et al. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. Antimicrob Agents Chemother. 2010 Jun;54(6):2365-70. [Content Brief]
- [3]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]
Keywords
